Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIVE-IPF: TPE, Rituximab and IVIG for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
NCT03286556Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Sep 2018
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, immune globulin in idiopathic pulmonary fibrosis (IPF), sponsored by University of Alabama at Birmingham. Started Sep 2018; status: completed.
02
Drugs
rituximabimmune globulin
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03286556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03286556.